Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LeonaBio, Inc.LONA · Entity 1487 | Director | June 23, 2026 | June 24, 2026 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director · CHIEF EXECUTIVE OFFICER | September 08, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LeonaBio, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.35 · Expires 2036-06-22 | Direct | 28,000 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 28,000 · Balance 28,000 F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.
Vaxcyte, Inc.
Report date September 08, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 429,902 |
Reported balance
After 2026-09-08 transaction · row 1
1 source rowRow 1 · 2026-09-08 · Tax withholding · Disposed 17,056 · Balance 429,902 F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. |
| Common StockSEC Table I · non-derivative | IndirectBy Children's Trust | 133,215 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 133,215 F2: Shares are held directly by a trust for the benefit of the Reporting Person's son. |
| Common StockSEC Table I · non-derivative | IndirectBy Children's Trust | 133,215 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 133,215 F3: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
F2: Shares are held directly by a trust for the benefit of the Reporting Person's son.
F3: Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2024 Filed Dec 10, 2024 21:10 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 961 | $92.06 | $88,469.66 |
DisclosureSEC source: 0001649094-24-000121 · wk-form4_1733865045.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 136,437 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $91.615 to $92.61. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 00:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,242 | $94.06 | $210,882.52 |
DisclosureSEC source: 0001649094-24-000115 · wk-form4_1733271300.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 450,301 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $93.72 to $94.61. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 00:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,409 | $93.06 | $131,122.95 |
DisclosureSEC source: 0001649094-24-000115 · wk-form4_1733271300.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 452,543 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $92.72 to $93.65. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 00:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 11,349 | $92.06 | $1,044,788.94 |
DisclosureSEC source: 0001649094-24-000115 · wk-form4_1733271300.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 453,952 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $91.68 to $92.67. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 21:42 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GiftCommon Stock | 710 | $0.00 | $0.00 |
DisclosureSEC source: 0001649094-24-000111 · wk-form4_1732052527.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465,301 F1 · shares: Represents a bona fide gift of the Issuer's Common Stock to a non-profit educational institution made via a donor advised fund. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantPerformance Restricted Stock Units · Derivative | 80,625 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001649094-24-000105 · wk-form4_1731116774.xml · derivative · entry 16 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,625 Underlying: Common Stock · 80,625 shares Expires 2034-11-06 F10 · derivative.exercise_date: Represents the target number of shares of Issuer's Common Stock underlying an award of performance restricted stock units ("PSUs"). Each PSU represents the contingent right to receive one share of the Issuer's Common Stock. The attainment of the performance vesting condition will be based on the Issuer's percentile rank within a peer group based on total shareholder return ("TSR") during a four-year performance period that commenced on November 7, 2024, the Grant Date, subject to the Reporting Person's continuous service with the Issuer through completion of the performance period. The actual number of shares of the Issuer's Common Stock deliverable with respect to the award varies based on performance and ranges from 0% to 250% of the target number of shares. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantPerformance Stock Option (right to buy) · Derivative | 197,784 | $0.00 Strike: $102.70 | $0.00 |
DisclosureSEC source: 0001649094-24-000105 · wk-form4_1731116774.xml · derivative · entry 15 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 197,784 Underlying: Common Stock · 197,784 shares Expires 2034-11-06 F9 · derivative.exercise_date: As part of a company-wide grant to all eligible employees of the Issuer, on November 7, 2024 (the "Grant Date"), the Reporting Person was granted a performance stock option to purchase 197,784 shares of the Issuer's Common Stock at a per share exercise price of $102.70. The option is subject to (1) a service-based vesting condition (vesting as to one-third of the shares on each of the third, fourth and fifth anniversaries of the Grant Date) and (2) a performance-vesting condition (which generally requires that the trading price of the Issuer's Common Stock average, over a one-year period, is at least $154.05 (150% of the Grant Date closing price)). Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001649094-24-000105 · wk-form4_1731116774.xml · derivative · entry 14 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 202,717 Underlying: Common Stock · 16,000 shares Expires 2030-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 14,129 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001649094-24-000105 · wk-form4_1731116774.xml · derivative · entry 13 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,198 Underlying: Common Stock · 14,129 shares Expires 2028-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 663 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001649094-24-000105 · wk-form4_1731116774.xml · derivative · entry 12 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 663 shares Expires 2025-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 16,000 | $5.35 | $85,600.00 |
DisclosureSEC source: 0001649094-24-000105 · wk-form4_1731116774.xml · nonDerivative · entry 11 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 14,129 | $2.03 | $28,681.87 |
DisclosureSEC source: 0001649094-24-000105 · wk-form4_1731116774.xml · nonDerivative · entry 10 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 450,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 663 | $0.04 | $26.52 |
DisclosureSEC source: 0001649094-24-000105 · wk-form4_1731116774.xml · nonDerivative · entry 9 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 435,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 105 | $105.50 | $11,077.50 |
DisclosureSEC source: 0001649094-24-000105 · wk-form4_1731116774.xml · nonDerivative · entry 8 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 137,398 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F7 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 434 | $104.72 | $45,446.31 |
DisclosureSEC source: 0001649094-24-000105 · wk-form4_1731116774.xml · nonDerivative · entry 7 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 137,503 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $104.405 to $105.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F7 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 363 | $103.36 | $37,520.41 |
DisclosureSEC source: 0001649094-24-000105 · wk-form4_1731116774.xml · nonDerivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 137,937 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $103.28 to $104.08. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F7 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 281 | $102.64 | $28,840.44 |
DisclosureSEC source: 0001649094-24-000105 · wk-form4_1731116774.xml · nonDerivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 138,300 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F6 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $102.09 to $103.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F7 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 116 | $105.50 | $12,238.00 |
DisclosureSEC source: 0001649094-24-000105 · wk-form4_1731116774.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 137,398 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 377 | $104.71 | $39,475.29 |
DisclosureSEC source: 0001649094-24-000105 · wk-form4_1731116774.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 137,514 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $104.405 to $105.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 463 | $103.43 | $47,889.94 |
DisclosureSEC source: 0001649094-24-000105 · wk-form4_1731116774.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 137,891 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $103.28 to $104.08. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 227 | $102.68 | $23,308.36 |
DisclosureSEC source: 0001649094-24-000105 · wk-form4_1731116774.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 138,354 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $102.19 to $103.06. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 23:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,733 | $108.50 | $188,030.50 |
DisclosureSEC source: 0001649094-24-000091 · wk-form4_1730763998.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 435,219 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $107.97 to $108.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 23:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,312 | $107.34 | $355,506.77 |
DisclosureSEC source: 0001649094-24-000091 · wk-form4_1730763998.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 436,952 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $106.865 to $107.845. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 23:46 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 9,955 | $106.35 | $1,058,714.25 |
DisclosureSEC source: 0001649094-24-000091 · wk-form4_1730763998.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 440,264 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $105.855 to $106.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 00:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 537 | $110.20 | $59,179.55 |
DisclosureSEC source: 0001649094-24-000080 · wk-form4_1728433940.xml · nonDerivative · entry 8 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 138,581 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F10 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $110.16 to $111.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F7 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 00:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,849 | $109.43 | $202,334.22 |
DisclosureSEC source: 0001649094-24-000080 · wk-form4_1728433940.xml · nonDerivative · entry 7 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 139,118 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F9 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $109.16 to $110.075. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F7 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 00:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 807 | $108.75 | $87,759.64 |
DisclosureSEC source: 0001649094-24-000080 · wk-form4_1728433940.xml · nonDerivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 140,967 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F8 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $108.14 to $109.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F7 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 00:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 356 | $107.50 | $38,268.58 |
DisclosureSEC source: 0001649094-24-000080 · wk-form4_1728433940.xml · nonDerivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 141,774 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $107.08 to $108.07. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F7 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's daughter. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 00:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 239 | $110.35 | $26,373.17 |
DisclosureSEC source: 0001649094-24-000080 · wk-form4_1728433940.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 138,581 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F6 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $110.235 to $111.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 00:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,113 | $109.58 | $231,548.88 |
DisclosureSEC source: 0001649094-24-000080 · wk-form4_1728433940.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 138,820 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $109.17 to $110.16. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 00:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 887 | $108.72 | $96,437.30 |
DisclosureSEC source: 0001649094-24-000080 · wk-form4_1728433940.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 140,933 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $108.11 to $109.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 00:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 310 | $107.27 | $33,253.08 |
DisclosureSEC source: 0001649094-24-000080 · wk-form4_1728433940.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Indirect · By Children's Trust Disclosed balance after: 141,820 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $107.08 to $108.07. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held directly by a trust for the benefit of the Reporting Person's son. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001649094-24-000077 · wk-form4_1727986643.xml · derivative · entry 15 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 218,717 Underlying: Common Stock · 20,000 shares Expires 2030-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001649094-24-000077 · wk-form4_1727986643.xml · derivative · entry 14 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 238,717 Underlying: Common Stock · 20,000 shares Expires 2030-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,474 | $114.98 | $629,411.47 |
DisclosureSEC source: 0001649094-24-000077 · wk-form4_1727986643.xml · nonDerivative · entry 11 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 450,219 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F10 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $114.80 to $115.32. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 9,627 | $114.28 | $1,100,183.19 |
DisclosureSEC source: 0001649094-24-000077 · wk-form4_1727986643.xml · nonDerivative · entry 10 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 455,693 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F9 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $113.76 to $114.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,899 | $113.37 | $555,399.63 |
DisclosureSEC source: 0001649094-24-000077 · wk-form4_1727986643.xml · nonDerivative · entry 9 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 465,320 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F8 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $112.745 to $113.735. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 20,000 | $5.35 | $107,000.00 |
DisclosureSEC source: 0001649094-24-000077 · wk-form4_1727986643.xml · nonDerivative · entry 8 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 470,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 6,266 | $114.93 | $720,176.44 |
DisclosureSEC source: 0001649094-24-000077 · wk-form4_1727986643.xml · nonDerivative · entry 7 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 450,219 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F7 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $114.705 to $115.28. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 9,429 | $114.20 | $1,076,820.09 |
DisclosureSEC source: 0001649094-24-000077 · wk-form4_1727986643.xml · nonDerivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 456,485 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F6 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $113.705 to $114.68. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,305 | $113.35 | $487,954.53 |
DisclosureSEC source: 0001649094-24-000077 · wk-form4_1727986643.xml · nonDerivative · entry 5 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 465,914 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $112.705 to $113.65. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 20,000 | $5.35 | $107,000.00 |
DisclosureSEC source: 0001649094-24-000077 · wk-form4_1727986643.xml · nonDerivative · entry 4 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 470,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,288 | $114.99 | $493,055.68 |
DisclosureSEC source: 0001649094-24-000077 · wk-form4_1727986643.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 450,219 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $114.77 to $115.275. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 7,088 | $114.27 | $809,967.02 |
DisclosureSEC source: 0001649094-24-000077 · wk-form4_1727986643.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 454,507 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $113.76 to $114.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,624 | $113.38 | $410,892.74 |
DisclosureSEC source: 0001649094-24-000077 · wk-form4_1727986643.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 461,595 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 12, 2024. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $112.76 to $113.735. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:18 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 13,669 | $110.15 | $1,505,640.35 |
DisclosureSEC source: 0001649094-24-000064 · wk-form4_1725571075.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465,219 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated September 4, 2024 were sold by the Reporting Person. Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 20:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001649094-24-000056 · wk-form4_1724705892.xml · derivative · entry 6 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 167,327 Underlying: Common Stock · 15,000 shares Expires 2028-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 20:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 8,314 | $79.25 | $658,906.12 |
DisclosureSEC source: 0001649094-24-000056 · wk-form4_1724705892.xml · nonDerivative · entry 3 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 478,888 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $78.985 to $79.56. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 20:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 6,686 | $78.65 | $525,860.59 |
DisclosureSEC source: 0001649094-24-000056 · wk-form4_1724705892.xml · nonDerivative · entry 2 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 487,202 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 26, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $77.98 to $78.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 23, 2024 Filed Aug 26, 2024 20:58 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 15,000 | $2.03 | $30,450.00 |
DisclosureSEC source: 0001649094-24-000056 · wk-form4_1724705892.xml · nonDerivative · entry 1 PICKERING GRANT · CIK 0001258693 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 493,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.